Anticancer hybrids- a patent survey

Recent Patents on Anti-Cancer Drug Discovery

Volumn 9, Issue 3, 2014, Pages 303-339

  Nepali, Kunal ^a   Sharma, Sahil ^b   Kumar, Dinesh ^b   Budhiraja, Abhishek ^c   Dhar, Kanaya L ^d  

^a Sri Sai College of Pharmacy   (India)

^b GURU NANAK DEV UNIVERSITY   (India)

^c SHOOLINI UNIVERSITY   (India)

^d ISF COLLEGE OF PHARMACY   (India)

Author keywords

Anticancer; Design; Drug; Hybrids; Microtubule; Steroids

Indexed keywords

ANTINEOPLASTIC AGENT;

DRUG DESIGN; HUMAN; NEOPLASMS; PATENT;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; NEOPLASMS; PATENTS AS TOPIC;

EID: 84905637758     PISSN: 15748928     EISSN: 22123970     Source Type: Journal    
DOI: 10.2174/1574892809666140520150459     Document Type: Review

References (183)

1. Contelles JM, Soriano E. The medicinal chemistry of hybrid-based drugs targeting multiple sites of action. Curr Top Med Chem 2011; 11(22): 2714.
2. Viegas-Junior C, Danuello A, Da Silva BV, Barreiro EJ, Fraga CA. Molecular hybridization: A useful tool in the design of new drug prototypes. Curr Med Chem 2007; 14(17): 1829.
3. Biot C, Chibale K. Novel approaches to antimalarial drug discov-ery. Infec Dis Drug Targ 2006; 6: 173.
4. Tietze LF, Bell HP, Chandrasekhar S, Natural product hybrids as new leads for drug discovery. Angew Chem Int Ed 2003; 42 (34): 3996.
5. Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Disc Today 2004; 9(15): 641.
6. Hulsman N, Medema JP, Bos C, Jongejan A, Leurs R, Smit MJ, et al. Chemical insights in the concept of hybrid drugs: The antitu-mor effect of nitric oxide-donating aspirin involves a quinone me-thide but not nitric oxide nor aspirin. J Med Chem 2007; 50: 2424.
7. Sawyers C. Targeted cancer therapy. Nature 2004; 432: 294.
8. Petrelli A, Giordano S. From single- to multi-target drugs in cancer therapy: When aspecificity becomes an advantage. Curr Med Chem 2008; 15(5): 422.
9. Overington JP, Al-Lazikani B, Hopkins AL. How many drug tar- gets are there. Nat Rev Drug Discov 2006; 5(12): 993.
10. Bode AM, Dong ZG. Cancer prevention research - then and now. Nat Rev Cancer 2009; 9: 508s.
11. Zhan P, Liu XY. Designed multiple ligands: an emerging anti-HIV drug discovery paradigm. Curr Pharm Des 2009; 15:1893.
12. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 2005; 48: 6523.
13. Gediya LK, Njar VCO. Promise and challenges in drug discovery and development of hybrid anticancer drugs. Expert Opin Drug Discov 2009; 4(11): 1009.
14. Aina OH, Sroka TC, Chen ML, Lam KS. Therapeutic cancer targeting peptides. Biopolymers 2002; 66:184.
15. Boohaker RJ, Lee MW, Vishnubhotla P, Perez JM, Khaled AR. The use of therapeutic peptides to target and to kill cancer cells. Curr Med Chem 2012; 19: 3794.
16. Federico A, Zappavigna S, Romano M, Grieco P, Luce A, Marra M, et al. Urotensin-II receptor is over-expressed in colon cancer cell lines and in colon carcinoma in humans. Eur J Clin Invest 2014; 44: 285.
17. Grieco P, Franco R, Bozzuto G, Toccacieli L, Sgambato A, Marra M, et al. Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells. J Cell Biochem 2011; 112: 341.
18. Merlino F, Maro SD, Yousif AM, Caraglia M, Grieco P. Urotensin-II ligands: An overview from peptide to nonpeptide structures. J Amino Acids 2013; 10: 1155.
19. Ettore, N., Paolo, G., Paolo, R. Cyclic peptides acting as urotensin-II antagonist. WO023845 (2005).
20. Ettore, N., Paolo, G., Michele, C., Alfredo, B., Renato, F. Peptidic and non peptidic ligands for immunodetection for the receptor for urotensin II. WO095995 (2008).
21. Lamberts SWJ, Van der Lely AJ, Hofland LJ. New somatostatin analogs: Will they fulfil old promises? Eur J Endocrinol 2002; 14: 6701.
22. Capello A, Krenning EP, Bernard BF, Breeman WAP, Erion JL, Jong MD, et al. Anticancer activity of targeted proapoptotic pep-tides. J Nucl Med 2006; 47: 122.
23. Vitale G, Lupoli G, Guarrasi R, Colao A, Dicitore A, Gaudenzi G, et al. Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: In vitro and in vivo studies. J Clin Endocrinol Me-tab 2013; 98:1567.
24. Ferone D. Somatostatin and dopamine receptors. Tumor 2010; 96: 802.
25. Vendrell M, Soriano A, Casad V, Daz JL, Lavilla R, Canela EI, et al. Indoloquinolizidine-peptide hybrids as multiple agonists for D1 and D2 receptors. J Med Chem 2009; 4:1514.
26. Culler MD. Somatostatin-dopamine chimeras: A novel approach to treatment of neuroendocrine tumors. Horm Metab Res 2011; 43: 854.
27. Yang L, Horibe T, Kohno M, Haramoto M, Ohara K, Puri RK, et al. Targeting Interleukin-4 receptor with hybrid peptide for effective cancer therapy. Mol Cancer Ther 2012; 11: 235.
28. Horibe T, Kohno M, Haramoto M, Ohara K, Kawakami K. Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent. J Transl Med 2011; 9: 8.
29. Kohnoa M, Horibe T, Haramoto M, Yano Y, Ohara K, Nakajima O, et al. A novel hybrid peptide targeting EGFR-expressing cancers. Eur J Cancer 2011; 47: 773.
30. Jordan MA, Wilson L. Microtubules and actin filaments: Dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998; 10: 123.
31. Giannakakou P, Sackett D, Fojo TJ. Tubulin/microtubules: Still a promising target for new chemotherapeutic agents. Natl Cancer Inst 2003; 92:182.
32. Mangla V, Nepali K, Singh G, Singh J, Guru S, Gupta MK, et al.Strucure activity relationship of arylidene pyrrolo and pyrido [2,1-b] quinazolones as cytotoxic agents: Synthesis, SAR studies, biological evaluation and docking studies. Med Chem 2013; 9: 642.
33. Jordan A, Hadfield JA, Lawrence NJ, McGown AT. Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindle. Med Res Rev 1998; 18: 259.
34. Downing KH, Nogales E. New insights into microtubule structure and function from the atomic model of tubulin. Eur Biophys J 1998; 27:431.
35. Nogales E. A structural view of microtubule dynamics. Cell Mol Life Sci 1999; 56:133.
36. Wilson L, Jordan MA, Morse A, Margolis RL. Interaction of vin-blastine with steady-state microtubules in vitro. J Mol Biol 1982; 159: 125.
37. Snyder JP, Nettles JH, Cornett B, Downing KH, Nogales E. The binding conformation of Taxol in beta-tubulin: A model based on electron crystallographic density. PNAS 2001; 98: 5312.
38. Schiff PB, Fant J, Horwiz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277: 665.
39. Haggarty SJ, Mayer TU, Miyamoto DT, Fathi R, King RW, Mitchinson TJ, et al. Dissecting cellular processes using small molecules: Identification of colchicine-like, taxol-like and other small molecules that perturb mitosis. Chem Biol 2000; 7: 275.
40. Angerer EV. Tubulin as a target for anticancer drugs. Curr Opin Drug Discovery Develop 2000; 3: 575.
41. Wood KW, Cornwell WD, Jackson JR. Past and future of the mitotic spindle as an oncology target. Curr Opin Pharmacol 2001; 1: 370.
42. Romagnoli R, Baraldi PG, Carrion MD, Cruz-Lopez O, Cara CL, Balzarini J, et al. Hybrid alpha-bromoacryloylamido chalcones. Design, synthesis and biological evaluation. Bioorg Med Chem Let 2009; 19: 2022.
43. Kamal A, Ramakrishna G, Raju P, Viswanath A, Ramaiah MJ, Balakishan G, et al. Synthesis and anti-cancer activity of chalcone linked imidazolone. Bioorg Med Chem Lett 2010; 20:4865.
44. Nagaraju M, Deepthi EG, Ashwini C, Vishnuvardhan MVPS, Nayak L, Chandra R, et al. Synthesis and selective cytotoxic activity of novel hybrid chalcones against prostate cancer cells. Bioorg Med Chem Let 2012; 22: 4314.
45. Mourad MAE, Abdel-Aziz M, Abuo-Rahma GEDAA, Farag HH. Design, synthesis and anticancer activity of nitric oxide donat-ing/chalcone hybrids. Eur J Med Chem 2012; 54: 907.
46. Singh P, Raj R, Kumar V, Mahajan MP, Bedi PMS, Kaur T, et al. 1,2,3-Triazole tethered p-lactam-chalcone bifunctional hybrids: Synthesis and anticancer evaluation. Eur J Med Chem 2012; 47: 594.
47. Gu X, Ren Z, Tang X, Peng H, Mad Y, Lai Y, Peng S, Zhang Y, et al. Synthesis and biological evaluation of bifendate-chalcone hybrids as a new class of potential P-glycoprotein inhibitors. Bioorg Med Chem 2012; 20: 2540.
48. Singh J, Sharma S, Saxena AK, Nepali K, Bedi PMS. Synthesis of 1,2,3-triazole tethered bifunctional hybrids by click chemistry and their cytotoxic studies. Med Chem Res 2013; 22: 3160.
49. Kamal A, Bharathi VB, Reddy JS, Ramaiah JM, Dastagiri D, Reddy MK, et al. Synthesis and biological evaluation of 3,5- diaryl isoxazoline/isoxazole linked 2,3-dihydroquinazolinone hybrids as anticancer agents. Eur J Med Chem 2011; 46: 691.
50. Parihar S, Gupta A, Chaturvedi AK, Agarwal J, Luqman S, Chang-kija B, et al. Gallic acid based steroidal phenstatin analogs for selective targeting of breast cancer cells through inhibiting tubulin polymerization. Steroids 2012; 77: 878.
51. Li S, Yang X, Yang B, He Q, Hu Y. Novel hybrids from lamellarin D and combretastatin A4 as cytotoxic agents. Eur J Med Chem 2010; 45: 11.
52. Banwell MG, Hamel E, Hockless DCR, Verdier-Pinard P, Willis AC, Wong DJ, et al. 4,5- Diaryl-1H-pyrrole-2-carboxylates as combretastatin A-4/lamellarin T hybrids: Synthesis and evaluation as anti-mitotic and cytotoxic agents. Bioorg Med Chem 2006; 14:4267.
53. Kamal A, Mallareddy A, Ramaiah MJ, Pushpavalli SNCVL, Suresh P, Kishor C, et al. Synthesis and biological evaluation of combretastatin-amidobenzothiazole conjugates as potential anticancer agents. Eur J Med Chem 2012; 56: 166.
54. Rasolofonjatovo E, Provot O, Hamze A, Bignon J, Thoret S, Brion JD. Alami M, et al. Regioselective hydrostannation of diarylal-kynes directed by a labile ortho bromine atom: an easy access to sterodefined triaylolefins, hybrids of combretastatin A-4 and iso-combretastatin A-4. Eur J Med Chem 2010; 45: 3617.
55. Quintin J, Roullie C, Thoret S, Lewin G. Synthesis and anti-tubulin evaluation of chromone-based analogs of combretastatins. Tetrahedron 2006; 62: 4038.
56. Bourdron J, Commeiras L, Barbier P, Bourgarel-Rey V, Pasquier E, Vanthuyne N, et al. Caulerpenyne-colchicine hybrid: Synthesis and biological evaluation. Bioorg Med Chem 2006; 15: 5540.
57. Malysheva YB, Combes S, Allegro D, Peyrot V, Knochel P, Gavryushin AE, et al. Synthesis and biological evaluation of novel anticancer bivalent colchicine-tubulizine hybrids. Bioorg Med Chem 2012; 20: 4271.
58. Wardle NJ, Kalber T, Bell JD, Bligh SWA. Synthesis and characterization of a novel tubulin-directed DO3A-colchicine conjugate with potential theranostic features. Bioorg Med Chem 2011; 21: 3346.
59. Zefirova ON, Nurieva EV, Lemcke H, Ivanov AA, Shishov DV, Weiss DG, et al. Design, synthesis, and bioactivity of putative tubulin ligands with admantane core. Bioorg Med Chem Lett 2008; 18: 5091.
60. Andres CJ, Bernardo JE, Yan Q, Hastie SB, Macdonald TL. Com-bretatropones-hybrids of combretastatin and colchicine-synthesis and biochemical evaluation. Bioorg Med Chem Lett 1993; 3: 565.
61. Passarella D, Peretto B, Yepes RBY, Cappelletti G, Cartelli D, Ronchi C, et al. Synthesis and biological evaluation of novel thio-colchicine-podophyllotoxin conjugates. Eur J Med Chem 2010; 45: 219.
62. Zhang X, Zhang J, Tong L, Luo Y, Su M, Zang Y, et al. The discovery of colchicine - SAHA hybrids as a new class of antitumor agents. Bioorg Med Chem 2013; 21(11): 3240.
63. Zefirova ON, Nurieva EV, Shishov DV, Baskin II, Fuchs F, Lemcke H, et al. Synthesis and SAR requirements of adamantane-colchicine conjugates with both microtubule depolymerizing and tubulin clustering activities. Bioorg Med Chem 2011; 19: 5529.
64. Kamal A, Laxman E, Khanna R, Reddy PSMM, Rehana T, Ari-fuddi AK, et al. Design, synthesis, biological evaluation and QSAR studies of novel bisepipodophyllotoxins as cytotoxic agents. Bioorg Med Chem 2004; 12: 4197.
65. Castro MA, del Corral JMM, García PA, Rojo MV, Bento AC, Mollinedo F, et al. Lignapurines: A new family of hybrids between cyclolignans and purines, synthesis and biological evaluation. Eur J Med Chem 2012; 58: 377.
66. Kamal A, Suresh P, Ramaiah J, Mallareddy A, Kumar BA, Raju P, et al. Synthesis and biological evaluation of 4(3- acrylamidopodo-phyllotoxin congeners as DNA damaging agents. Bioorg Med Chem 2011; 19: 4589.
67. Kamal A, Mallareddy A, Suresh P, Nayak VL, Shetti RVCRNC, Rao NS, et al. Synthesis and anticancer activity of 4 (3-alkylamidochalcone and 4p-cinnamido linked podophyllotoxins as apoptotic inducing agents. Eur J Med Chem 2012; 47: 530.
68. Wittman MD, Kadow JF, Vyas DM, Lee FL, Rose WC, Long BH, et al. Synthesis and antitumor activity of novel paclitaxel- chloam-bucil hybrids. Bioorg Med Chem Lett 2001; 11: 811.
69. Smith AB, Sugasawa K, Atasoylu O, Yang C-P, Horwitz SB. Design and synthesis of (+)- discodermolide- paclitaxel hybrids leading to enhanced biological activity. J Med Chem 2011; 54(18): 6319.
70. Ngo QA, Roussi F, Cormier A, Thoret S, Knossow M, Guenard D, et al. Synthesis and biological evaluation of vinca alkaloids and phomopsin hybrids. J Med Chem 2009; 52: 134.
71. Passarella D, Giardini A, Peretto B, Fontana G, Sacchetti A, Sil-vani A, et al. Inhibitors of tubulin polymerization: Synthesis and biological evaluation of hybrids of vindoline, anhydrovinblastine and vinorelbine with thiocolchicine, podophyllotoxin and baccatin III. Bioorg Med Chem 2008; 16: 6269.
72. Ma J, Li S, Reed K, Guo P, Gallo JM. Pharmacodynamic-mediated effects of the angiogenesis inhibitor SU5416 on the tumor disposition of temozolomide in subcutaneous and intracerebral glioma xenograft models. J Pharmacol Exp Ther 2003; 305: 833.
73. Lane ME, Yu B, Rice A, Lipson C, Liang C, Sun L, et al. A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res 2001; 61: 6170.
74. Hamid MA, Hafez AA, El-Koussi N, Mahfouz N, Innocenti A, Supuran CT, et al. Design, synthesis, and docking studies of new 1,3,4-thiadiazole-2-thione derivatives with carbonic anhydrase inhibitory activity. Bioorg Med Chem 2007; 15: 6975.
75. Pathak T, Azidonucleosides: Synthesis, reactions, and biological properties. Chem Rev 2002; 102:1623.
76. Kumar K, Sagar S, Esau L, Kaur M, Kumar V. Synthesis of novel 1H-1,2,3-triazole tethered C-5 substituted uracil-isatin conjugates and their cytotoxic evaluation. Eur J Med Chem 2012; 58:153.
77. Singh P, Sharma P, Anand A, Bedi PMS, Kaur T, Saxena AK, Kumar V, et al. Azide-alkyne cycloaddition en route to novel 1H- 1,2,3-triazole tethered isatin conjugates with in vitro cytotoxic evaluation. Eur J Med Chem 2012; 55: 455.
78. Solomon VR, Hua C, Lee H. Hybrid pharmacophore design and synthesis of isatin-benzothiazole analogs for their anti-breast cancer activity. Bioorg Med Chem 2009; 17: 7585.
79. Solomon VR, Hua C, Lee H. Design and synthesis of anti-breast cancer agents from 4-piperazinylquinoline: A hybrid pharma-cophore approach. Bioorg Med Chem 2010; 18: 1563.
80. Ramshid PK, Jagadeeshan S, Krishnan A, Mathew M, Nair SA, Pillai MR, et al. Synthesis and in vitro evaluation of some isatin-thiazolidinone hybrid analogs as anti-proliferative agents. Med Chem 2010; 6: 306.
81. Shi Y, Zhou C. Synthesis and evaluation of a class of new cou-marin triazole derivatives as potential antimicrobial agents. Bioorg Med Chem Lett 2011; 21: 956.
82. Hur SY, Kim TE, Park YG, Kim JR, Kim JW. Natural compounds, fraxin and chemicals structurally related to fraxin protect cells from oxidative stress. Exp Mol Med 2005; 37:436.
83. Egan DA, Cox D, Kennedy OR, Moran, Prosser E, Thornes RD, et al. The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds. Drugs Metab Rev 1990; 22: 503.
84. Modranka JN, Nawrot E, Graczyk J. In vivo antitumor, in vitro antibacterial activity and alkylating properties of phosphorohydra-zine derivatives of coumarin and chromone. Eur J Med Chem 2006; 41:1301.
85. Karali N, Kocabalkanli A, Gursoy A, Ates O. Synthesis and antitu-bercular activity of 4-(3-coumarinyl)-3-cyclohexyl-4-thiazolin-2-one benzylidenehydrazones. Farmaco 2002; 57: 589.
86. Cacic M, Trkovnik M, Cacic F, Schon EH. Synthesis and antimicrobial activity of some derivatives of (7-hydroxy-2-oxo-2H-chromen-4-yl)-acetic acid hydrazide. Molecules 2006; 11:134.
87. Hoult JRS, Paya M. Pharmacological and biochemical actions of simple coumarins: Natural products with therapeutic potential. Gen Pharmacol 1996; 27: 713.
88. Devji T, Reddy C, Woo C, Awale S, Kadota S, Corrio-Moniz D, et al. Pancreatic anticancer activity of a novel geranylgeranylated coumarin derivative. Bioorg Med Chem Lett 2011; 21: 5770.
89. Reddy NS, Mallireddigari MR, Cosenza S, Gumireddy K, Bell SC, Reddy EP, Reddy MVR, et al. Synthesis of new coumarin 3-(N-aryl) sulfonamides and their anticancer activity. Bioorg Med Chem Lett 2004; 14: 4093.
90. Xue H, Lu X, Zheng P, Liu L, Han C, Hun J, et al. Highly suppressing wild-type HIV-1 and Y181C mutant HIV-1 strains by 10-chloromethyl-11-demethyl-12-oxo-calanolide a with druggable profile. J Med Chem 2010; 53:1397.
91. Manvar A, Bavishi A, Radadiya A, Patel J, Vora V, Dodia N, et al. Diversity oriented design of various hydrazides and their in vitro evaluation against Mycobacterium tuberculosis H37Rv strains. Bioorg Med Chem Lett 2011; 21: 4728.
92. Yeh J-Y, Coumar MS, Horng J-T, Shiao H-Y, Lee H-L. Anti-influenza drug discovery: Structure-activity relationship and mechanistic insight into novel angelicin derivatives. J Med Chem 2010; 53: 1519.
93. Anand P, Singh B, Singh N. A review on coumarins as acetylcho-linesterase inhibitors for Alzheimer's disease. Bioorg Med Chem 2012; 20: 1175.
94. Piazzi L, Cavalli A, Colizzi F, Belluti F, Bartolini M, Mancinni F, et al. Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg Med Chem Lett 2008; 18:423.
95. Lin C-M, Huang S-T, Lee F-W, Kuo H-S, Lin MH. 6-Acyl-4-aryl/alkyl-5,7-dihydroxycoumarins as anti-inflammatory agents. Bioorg Med Chem 2006; 14: 4402.
96. Curini M, Epifano F, Maltese F, Marcotullio MC, Gonzales SP, Rodriguez JC, et al. Synthesis of collinin, an antiviral coumarin. Aust J Chem 2003; 56: 59.
97. Shi Y, Zhou C. Synthesis and evaluation of a class of new cou-marin triazole derivatives as potential antimicrobial agents. Bioorg Med Chem Lett 2011; 21: 956.
98. Amin KM, Eissa AAM, Abou-Seri SM, Awadallah FM, Hassan GS. Synthesis and biological evaluation of novel coumarin-pyrazoline hybrids endowed with phenylsulfonyl moiety as antitu-mor agents. Eur J Med Chem 2013; 60:187.
99. Belluti F, Fontana G, Bo LD, Carenini N, Giommarelli C, Zunino F, et al. Design, synthesis and anticancer activities of stilbene- coumarin hybrid compounds: Identification of novel proapoptotic agents. Bioorg Med Chem 2010; 18: 3543.
100. Paul K, Bindal S, Luxami V. Synthesis of new conjugated cou-marin-benzimidazole hybrids and their anticancer activity. Bioorg Med Chem 2013; 23(12): 3667.
101. Sashidhara KV, Kumar A, Kumar M, Sarkar J, Sinha S. Synthesis and in vitro evaluation of novel coumarin-chalcone hybrids as potential anticancer agents. Bioorg Med Chem 2010; 10: 7205.
102. Sashidhara KV, Rao AS, Sharma K, Palnati GR, Bathula SD. Discovery of coumarin-monastrol hybrid as potential antibreast tumor-specific agent. Eur J Med Chem 2013; 60: 120.
103. Soukpoe-Kossi CNN, Teaux CD, Asselin E, Riahi TH, Ali G. Berube. DNA interaction with novel antitumor estradiol-platinum(II) hybrid molecule: A comparative study with cisplatin drug. DNA and Cell Biol 2008; 27:101.
104. Gupta A, Saha P, Descôteaux C, Leblanc V, Asselin E, Bérubé G, et al. Design, synthesis and biological evaluation of estradiol-chlorambucil hybrids as anticancer agents. Bioorg Med Chem Lett 2010; 20:1614.
105. Kuduk SD, Zeng FF, Sepp-Lorenzion L, Rosen N, Danishefsky SJ. Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett 1999; 9:1233.
106. Kuduk SD, Harris CR, Zheng FF, Sepp-Lorenzino L, Ouerfelli Q, Rosen N, et al. Synthesis and evaluation of geldanamycin-testosterone hybrids. Bioorg Med Chem Lett 2000; 10:1303.
107. Adsule S, Banerjee S, Ahmed F, Padhye S, Sarkar FH. Hybrid anticancer agents: Isothiocyanate-progesterone conjugates as che-motherapeutic agents and insights into their cytotoxicities. Bioorg Med Chem Lett 2010; 20:1247.
108. Trafalis DTP. Hybrid aza-steroid alkylators in the treatment of colon cancer. Cancer Lett 2006; 43: 202.
109. Soukpoe-Kossi CNN, Teaux CD, Asselin E, Ali H Riahi T, Berube G. DNA interaction with novel antitumor estradiol-platinum(II) hybrid molecule: A comparative study with cisplatin drug. Dna and Cell Biology 2008; 27:101.
110. Mandeville JP, Debnath C, Mandal SK, Leblanc V, Parent S, As-selin É, et al. Design, synthesis and biological evaluation of estra-diol-PEG-linked platinum(II) hybrid molecules: Comparative molecular modeling study of three distinct families of hybrids. Steroids 2011; 76: 94.
111. Bansal R, Guleria S, Thota S, Hartmann RW, Zimmer C. Synthesis of imidazole-derived steroidal hybrids as potent aromatase inhibitors. Med Chem Res 2013; 22: 692.
112. Kamal A, Rao MV, Laxman N, Ramesh G, Reddy GSK. Recent developments in the design, synthesis and structure-activity relationship studies of pyrrolo[2,1-c][1,4]benzodiazepines as DNA-interactive antitumor antibiotics. Curr Med Chem Anti-Cancer Agents 2002; 2: 215.
113. Kohn KW. Anthramycin. In Antibiotics III Mechanism of Action of Antimicrobial and Antitumor Agents. Corcoran JW, Hahn FE. Eds. New York: Springer-Verlag, 1975.
114. Hurley LH, Petrusek RL. Proposed structure of the anthramycin-DNA adduct. Nature 1979; 282: 529.
115. Thurston DE, Bose DS. Synthesis of DNA-Interactive Pyrrolo[2,1-c][1,4]benzodiazepines. Chem Rev 1994; 94: 433.
116. Hurley LH, Thurston DE. Pyrrolo[1,4]benzodiazepine antitumor antibiotics: Chemistry, Interaction with DNA and biological implications. Pharm Res 1984; 1: 99.
117. Hurley LH. Pyrrolo(1,4)benzodiazepine antitumor antibiotics. Comparative aspects of anthramycin, tomaymycin and sibiromycin. J Antibiot 1977; 30: 349.
118. Cargill C, Bachmann E, Zbinden G. Effects of daunomycin and anthramycin on electrocardiogram and mitochondrial metabolism of the rat heart. J Natl Cancer Inst 1974; 53: 481.
119. Kamal A, Reddy KS, Khan MN, Shetti RV, Ramaiah MJ, Push-pavalli SN, et al. Synthesis, DNA-binding ability and anticancer activity of benzothiazole/benzoxazole-pyrrolo[2,1-c][1,4]benzodia-zepine conjugates. Bioorg Med Chem 2010; 18: 4747.
120. Kamal A, Reddy JS, Ramaiah MJ, Dastagiri D, Bharathi EV, Azhar MA, et al. Design, synthesis and biological evaluation of 3,5-diaryl-isoxazoline/isoxazole-pyrrolobenzodiazepine conjugates as potential anticancer agents. Eur J Med Chem 2010; 45: 3924.
121. Kamal A, Tekumalla V, Krishnan A, Bhadra MP, Bhadra U. Development of pyrrolo[2,1-c][1,4]benzodiazepine beta-galactoside prodrugs for selective therapy of cancer by ADEPT and PMT, Chem. Med Chem 2008; 3: 794.
122. Kamal A, Ramesh G, Ramulu P, Srinivas O, Rehana T, Sheelu G, et al. Design and synthesis of novel chrysene-linked pyrrolo[2,1-c][1,4]-benzodiazepine hybrids as potential DNA-binding agents. Bioorg Med Chem lett 2003; 13: 3451.
123. Kamal A, Ramesh G, Srinivas O, Ramulu P. Synthesis and anti-tumor activity of pyrene-linked pyrrolo [2,1-c]benzodiazepine hybrids. Bioorg Med Chem Lett 2004; 14: 471.
124. Bose DS, Idrees M, Todewale IK, Jakka NM, Rao JK. Hybrids of privileged structures benzothiazoles and pyrrolo[2,1-c] [1,4]benzodiazepin-5-one, and diversity-oriented synthesis of ben-zothiazoles. Eur J Med Chem 2012; 50: 27.
125. Kamal A, Srikanth YVV, Ramaiah MJ, Khan MNA, Reddy MK, Lavanya MAA, Pushpavalli SNCVL, Pal-Bhadra M, et al. Synthesis, anticancer activity and apoptosis inducing ability of bisindole linked pyrrolo[2,1-c][1,4]benzodiazepine conjugates. Bioorg Med Chem 2012; 22: 571.
126. Wang J-J, Shen Y-K, Hu W-P, Hsieh MC, Lin F-L, Hsu M-K, et al. Design, synthesis, and biological evaluation of pyrrolo[2,1-c][1,4]benzodiazepine and indole conjugates as anticancer agents. J Med Chem 2006; 49:1442.
127. Kamal A, Bharathi EV, Ramaiah MJ, Reddy JS, Dastagiri D, Viswanath A et al. Synthesis, anticancer activity and apoptosis inducing ability of anthranilamide-PBD conjugates. Bioorg Med Chem Lett 2010; 20: 3310.
128. Kamal A, Reddy BSN, Reddy GSK, Ramesh G. Design and synthesis of C-8 linked pyrrolobenzodiazepine-naphthalimide hybrids as anti-tumor agents. Bioorg Med Chem Lett 2002; 12: 1933.
129. Kamal A, Dastagiri D, Ramaiah MJ, Bharathi EV, Reddy JS, Balakishan G, et al. Synthesis, anticancer activity and mitochon-drial mediated apoptosis inducing ability of 2,5-diaryloxadiazole-pyrrolobenzodiazepine conjugates. Bioorg Med Chem 2010; 18: 6666.
130. Kim M-Y, Na Y, Vankayalapati H, Gleason-Guzman M, Hurley LH. Design, synthesis, and evaluation of psorosper-min/quinobenzoxazine hybrids as structurally novel antitumor agents. J Med Chem 2003; 46: 2958.
131. Song Y, Shao Z, Dexheimer TS, Scher ES, Pommier Y, Cushman M, et al. Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitors. J Med Chem 2010; 53: 1979.
132. Murty MSR, Rao BR, Katiki MR, Nath NLR, Anto RJ. Synthesis of piperazinyl benzothiazole/benzoxazole derivatives coupled with 1,3,4-oxadiazole-2-thiol: Novel hybrid heterocycles as anticancer agents. Med Chem Res 2013; 22: 4980.
133. Teaux CD, Brasseur K, Leblanc V, Parent S, Asselin E, Berube G, et al. SAR study of tyrosine-chlorambucil hybrid regioisomers; synthesis and biological evaluation against breast cancer cell lines. Med Chem Res 2012; 43: 923.
134. Graham LA, Suryadi J, West TK, Kucera GL, Bierbach U. Synthesis, aqueous reactivity, and biological evaluation of carboxylic acid ester-functionalized platinum-acridine hybrid anticancer agents. J Med Chem 2012; 55: 7817.
135. Natarajan A, Guo Y, Harbinski F, Fan Y-H, Chen H, Luus L, et al. Novel arylsulfoanilide-oxindole hybrid as an anticancer agent that inhibits translation initiation. J Med Chem 2004; 47: 4979.
136. Verma P, Kaur M, Singh P. Design, synthesis and anticancer activities of hybrids of indole and barbituric acids--identification of highly promising leads. Bioorg Med Chem Lett 2009; 19: 3054.
137. Descoteaux C, Brasseur K, Leblanc V, Parent S, Asselin E, Berube G. Design of novel tyrosine-nitrogen mustard hybrid molecules active against uterine, ovarian and breast cancer cell lines. Steroids 2012; 77: 403.
138. Romagnol R, Baraldi PG, Carrion MD, Cruz-Lopez O, Preti D, Tabrizi MA, et al. Hybrid molecules containing benzo[4,5]imidazo[1,2-d][1,2,4]thiadiazole and alpha- bromoacryloyl moieties as potent apoptosis inducers on human myeloid leukaemia cells. Bioorg Med Chem Lett 2007; 17: 2844.
139. Yang X-D, Wan W-C, Deng X-Y, Li Y, Yang L-J, Li L, et al. Design, synthesis and cytotoxic activities of novel hybrid compounds between 2-phenylbenzofuran and imidazole. Bioorg Med Chem Lett 2012; 22: 2726.
140. Wang X-Q, Liu L-X, Li Y, Sun CJ, Chen W, Li L, et al. Design, synthesis and biological evaluation of novel hybrid compounds of imidazole scaffold-based 2-benzylbenzofuran as potent anticancer agents. Eur J Med Chem 2013; 62: 111.
141. Zhou Y, Zhao Y, Boyle KMO, Murphy PV. Design, synthesis and biological evaluation of novel hybrid compounds of imidazole scaffold-based 2-benzylbenzofuran as potent anticancer agents. Bioorg Med Chem Lett 2006; 18: 954.
142. Li D, Wang L, Cai H, Zhang Y, Xu J. Synthesis and biological evaluation of novel furozan-based nitric oxide-releasing derivatives of oridonin as potential anti-tumor agents. Molecules 2012; 17: 7556.
143. Yee EMH, Pasquier E, Iskander G, Wood K, Black DS, Kumar N, et al. Synthesis of novel isoflavene-propranolol hybrids as anti-tumor agents. Bioorg Med Chem 2013; 21: 1652.
144. Duan Y-C, Ma Y-C, Zhang E, Shi X-J, Wang M-M, Ye X-W, et al. Design and synthesis of novel 1,2,3-triazole-dithiocarbamate hybrids as potential anticancer agents. Eur J Med Chem 2013; 62: 11.
145. Duan Y-C, Zheng YC, Li XC, Wang MM, Ye XW, Guan YY, et al. Design, synthesis and antiproliferative activity studies of novel 1,2,3-triazole-dithiocarbamate-urea hybrids. Eur J Med Chem 2013; 64: 99.
146. Kumar R, Gupta L, Pal P, Khan S, Singh N, Katiyar SB, et al. Synthesis and cytotoxicity evaluation of (tetrahydro-beta-carboline)-1,3,5-triazine hybrids as anticancer agents. Eur J Med Chem 2010; 45: 2265.
147. Ritson DJ, Moses JE. A fragment based click chemistry approach towards hybrid G-quadruplex ligands: Design, synthesis and biophysical evaluation. Tetrahedron 2012; 68: 197.
148. Descoteaux C, Leblanc V, Brasseur K, Gupta A, Asselin E, Berube G, et al. Synthesis of D- and L-tyrosine-chlorambucil analogs active against breast cancer cell lines. Bioorg Med Chem Lett 2010; 20: 7388.
149. Singh P, Kaur M, Holzer W. Synthesis and evaluation of indole, pyrazole, chromone and pyrimidine based conjugates for tumor growth inhibitory activities--development of highly efficacious cy-totoxic agents. Eur J Med Chem 2010; 45: 4968.
150. Romagnoli R, Baraldi G, Salvador MK, Camacho ME, Balzarini J, Bermejo J, et al. Anticancer activity of novel hybrid molecules containing 5-benzylidene thiazolidine-2,4-dione. Eur J Med Chem 2013; 63: 544.
151. Kumar PR, Behera M, Raghavulu K, Shree AJ, Yennam S. Synthesis of novel isoxazole-benzoquinone hybrids via 1,3-dipolar cy-cloaddition reaction as key step. Tetrahed 2012; 53: 4108.
152. Toshima K, Kimura T, Takano R, Ozawa T, Ariga A, Shima Y, et al. Molecular design, chemical synthesis and biological evaluation of quinoxaline-carbohydrate hybrids as novel and selective photo-induced DNA cleaving and cytotoxic agents. Tetrahed 2003; 59: 7057.
153. Kojima N, Fushimi T, Maezaki N, Tanaka T, Yamori T. Synthesis of hybrid acetogenins, alpha, beta-unsaturated-gamma-lactone-free nitrogen-containing heterocyclic analogs, and their cytotoxicity against human cancer cell lines. Bioorg Med Chem Lett 2008; 18(5):1637.
154. Alexander R. Kheradi, Saluta RA, Kucera G, Day GL, Bierbach CS. Synthesis and biological evaluation of platinum-acridine hybrid agents modified with bipyridine non-leaving groups. Bioorg & Med Chem Lett 2009; 19: 3423.
155. Hulsman N, Medema JP, Bos C, Jongejan A, Leurs R, Smit MJ, et al. Chemical insights in the concept of hybrid drugs: The antitu-mor effect of nitric oxide-donating aspirin involves a quinone me-thide but not nitric oxide nor aspirin. J Med Chem 2007; 50: 2424.
156. Chattopadhyay M, Kodela R, Olson KR, Kashfi K. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model. Biochem Biophys Res Commun 2012; 419: 523.
157. Israel, M., Seshadri, R. Hybrid nitrosoureidoanthracyclines having antitumor activity. US4973675 (1990).
158. Israel, M., Seshadri, R. N-alkyl and N-benzyl adriamycin derivatives. US4610977 (1986).
159. Israel, M., Modest, E.J. N-Trifluoroacetyladriamycin-14-alkanoates and therapeutic compositions containing same. US4035566 (1977).
160. Israel, M., Potti, G. N-Trifluoroacetyladriamycin-14-O-hemiglutarate and-hemiadipate and therapeutic compositions containing same. US4299822 (1981).
161. Wittman, M.D., Langley, D., Kadow, J.F. Hybrid antitumor compounds containing a cyclic enediyne and a DNA-binder. US5395849 (1995).
162. Xia, Z., Miller, G.G., Wiebe, L.I., Knaus, E.E. Dual action antican-cer prodrugs. CA2252144 (2000).
163. Ahmed, K., Reddy, S.P., Reddy, R.D. Pyrrolo(2,1-C)(1,4) benzodi-azepines dimmers as antitumor agents and process thereof. WO087716 (2004).
164. Ahmed, K., Gujjar, R., Poddutoori, R., Olepu, S. Pyrene-linked pyrrolo[2,1-C][1,4]benzodiazepine hybrids useful as anti-cancer agents. US0192677A1 (2004).
165. Ahmed, K., Gujjar, R., Poddutoori, R., Olepu, S. Pyrene-linked pyrrolo (2,1-C) (1,4) benzodiazepine derivatives useful as anti-cancer agents. WO087711 (2004).
166. Ahmed, K., Ramana, A.V., Babu, A.H. Pyrrolo[2,1-C][1,4]benzodiazepine hybrids and a process for the preparation thereof. WO020456A2 (2008), US0064685 (2008) & WO020455 (2008).
167. Ahmed, K., Bandari, R.P. The novel benzophenone hybrids as potential anticancer agents and a process for the preparation thereof. WO120235 (2008), US0174074 (2010) & EP2142506 (2010).
168. Ahmed, K., Bandari, R.P. Benzophenone hybrids as anticancer agents and processes for the preparation thereof. US8394954 (2013).
169. Ahmed, K., Bandari, R.P., Reddy, A.M. Benzophenone-piperazine linked pyrrolo[2,1-C][1,4]benzodiazepine hybrids as potential anti-cancer agents and process for the preparation thereof WO118749 (2009) & EP2262809 (2009).
170. Ahmed, K., Bandari, R.P., Reddy, A.M. Quinazoline linked pyr-rolo[2,1-C][1,4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof. US0046111 (2011), EP2265613 (2010) & WO109984 (2009).
171. Ahmed, K., Reddy, J.S., Dastagiri, D., Bharati, E.V. Isoxazoline linked pyrrolo[2,1-C][1,4]benzodiazepine hybrids as potential anti-cancer agents and the process for preparation thereof. US0118237 (2011), EP2271648 (2011) & WO118748 (2009).
172. Ahmed, K., Bandari, R.P., Reddy, A.M. Chalcone linked pyr-rolo[2,1-C][1,4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof. US0201600 (2011), EP2260039 (2013) & WO109986 (2009).
173. Ahmed, K., Pogula, P.K. Novel napthalimide-benzimidazole hybrids as potential antitumor agents and process for the preparation thereof. US0166346 (2011).
174. Ahmed, K., Shetty, R., Reddy, S.K., Reddy, A.M. The carbazole linked pyrrolo[2,1-C][1,4]benzodiazepine hybrids as potential anti-cancer agents and process for the preparation thereof. WO117668A1 (2011) & EP2403855 (2012).
175. Wu, J.H., Batist, G., Zhou, J., Geng, G., Lin, R. Hybrid-ionone and curcumin molecules as anticancer agents. US0230488 (2011).
176. Ahmed, K., Bharathi, E.V., Dastagiri, D., Reddy, J.S., Viswanath, A. Quinazolinone linked pyrrolo[2,1-C][1,4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof. US0095214 (2012), EP2350085 (2011) & WO058416 (2010).
177. Ahmed, K., Reddy, A.M., Paidakula, S., Chennamshetti, R.V.C.R.N. Benzylidine anthracenone linked pyrrolobenzodi-azepine hybrids useful as anticancer agents and process for the preparation thereof. US0142913 (2012).
178. Ahmed, K., Reddy, A.M., Paidakula, S., Shetti, R.V.C.R.N.C., Pal, H.C., Saxena, A.K. Benzothiazole hybrids useful as anticancer agents and process for the preparation thereof. WO104875 (2012) & US20140039190 (2014).
179. Ahmed, K., Viswanath, A., Chandra Murty, J.N.S., Bharathi, E.V., Ramakrishna, G., Sulthana, F. Diaryl ether linked pyrrolo[2,1-C][1,4]benzodiazepine hybrids and process for the preparation thereof. WO110840 (2012) & EP2836726 (2012).
180. Ahmed, K., Dudekula, D., Jonnala, S.R., Earla, V.B. Imidazothia-zole-chalcone derivatives as potential anticancer agents and process for the preparation thereof. WO045646 (2011), EP2488533 (2012) & US0271054 (2012).
181. Ahmed, K., Bharathi, E.V., Reddy, J.S., Dastagiri, D., Viswanath, A. Isoxazole/isoxazoline/combretastatin linked dihydroquinazoli-none hybrids as potential anticancer agents and process for the preparation thereof. US0283439 (2012), EP2350030 (2011), & WO058417 (2010).
182. Ahmed, K., Shetti, R.V.C.R.N.C, Reddy, S.K., Reddy, A.M. Car-bazole linked pyrrolo[2,1-C][1,4]benzodiazefine hybrids as potential anticancer agents and process for the preparation thereof. US0131336 (2013).
183. Chang, J., An, H., Yu, X., Guo, X. Nucleoside derivatives, synthesis methods and uses thereof for preparing anti-tumor and anti-virus medicaments. EP2615101 (2013) & EP2615101 (2014).